Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy

References

• Townsend W, Linch D. Hodgkin’s lymphoma in adults. Lancet. 2012;380(9844):836–847.
   PubMed Web of Science ®Google Scholar
• Cuccaro A, Bartolomei F, Cupelli E, et al. Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014053.
   PubMedGoogle Scholar
• André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Holtzman AL, Stahl JM, Zhu S, et al. Does the incidence of treatment-related toxicity plateau after radiation therapy: the long-term impact of integral dose in Hodgkin’s lymphoma survivors. Adv Radiat Oncol. 2019;4(4):699–705.
   PubMedGoogle Scholar
• Besson N, Pernin V, Zefkili S, et al. Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-Centre experience and review of the literature. Br J Radiol. 2016;89(1059):20150409.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Flampouri S, Zaiden R, et al. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. Int J Radiat Oncol Biol Phys. 2014;89(5):1053–1059.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84(2):449–455.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Cozzi L, Navarria P, et al. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiat Oncol. 2020;15(1):12.
   PubMed Web of Science ®Google Scholar
• Loap P, De Marzi L, Mirandola A, et al. Development and implementation of proton therapy for hodgkin lymphoma: challenges and perspectives. Cancers (Basel). 2021;13(15):3744.
   PubMed Web of Science ®Google Scholar
• Loap P, Mirandola A, De Marzi L, et al. Current situation of proton therapy for Hodgkin lymphoma: from expectations to evidence. Cancers (Basel). 2021;13(15):3746.
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107(3):267–273.
   PubMed Web of Science ®Google Scholar
• Loap P, Goudjil F, Dendale R, et al. Clinical and technical considerations for mediastinal Hodgkin lymphoma protontherapy based on a single-center early experience. Cancer Radiother. 2021;25:779–785.
   PubMed Web of Science ®Google Scholar
• Ntentas G, Dedeckova K, Andrlik M, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most? Pract Radiat Oncol. 2019;9(3):179–187.
   PubMed Web of Science ®Google Scholar
• Tambas M, Steenbakkers RJHM, van der Laan HP, et al. First experience with model-based selection of head and neck cancer patients for proton therapy. Radiother Oncol. 2020;151:206–213.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
   PubMed Web of Science ®Google Scholar
• Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31–S34.
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–243.
   PubMed Web of Science ®Google Scholar
• Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107:djv008.
   PubMedGoogle Scholar
• van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257–2265.
   PubMed Web of Science ®Google Scholar
• Duane F, Aznar MC, Bartlett F, et al. A cardiac contouring atlas for radiotherapy. Radiother Oncol. 2017;122(3):416–422.
   PubMed Web of Science ®Google Scholar
• Socha J, Rygielska A, Uziębło-Życzkowska B, et al. PO-1177 a heart valves contouring atlas on average intensity projection 4D-CT for lung cancer radiotherapy. Radiother Oncol. 2021;161:S975–S977.
   Web of Science ®Google Scholar
• Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):10–18.
   PubMed Web of Science ®Google Scholar
• Hodgkin lymphoma | Cancer Research UK [Internet]. [cited 2021 Jun 18]. Available from: https://www.cancerresearchuk.org/about-cancer/hodgkin-lymphoma.
   Google Scholar
• Bröckelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 2018;131(15):1666–1678.
   PubMed Web of Science ®Google Scholar
• Filly R, Bland N, Castellino RA. Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Radiology. 1976;120(2):277–281.
   PubMed Web of Science ®Google Scholar
• PTCOG - facilities in operation [Internet]. [cited 2021 Oct 28]. Available from: https://www.ptcog.ch/index.php/facilities-in-operation.
   Google Scholar
• Vega RBM, Mohammadi H, Patel SH, et al. Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2022;112(1):158–166.
   Google Scholar
• Loap P, Beddok A, Cao KI, et al. Clinical practice of breast cancer protontherapy: a single-Centre experience from selection to treatment. Cancer Radiother. 2021;25:358–365.
   PubMed Web of Science ®Google Scholar
• Loap P, Tkatchenko N, Goudjil F, et al. Cardiac substructure exposure in breast radiotherapy: a comparison between intensity modulated proton therapy and volumetric modulated arc therapy. Acta Oncol. 2021;60:1038–1044.
   PubMed Web of Science ®Google Scholar
• Loap P, De Marzi L, Almeida CE, et al. Hadrontherapy techniques for breast cancer. Crit Rev Oncol Hematol. 2022;169:103574.
   PubMed Web of Science ®Google Scholar
• Stick LB, Lorenzen EL, Yates ES, et al. Selection criteria for early breast cancer patients in the DBCG proton trial - the randomised phase III trial strategy. Clin Transl Radiat Oncol. 2021;27:126–131.
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–998.
   PubMed Web of Science ®Google Scholar
• Weber DC, Langendijk JA, Grau C, et al. Proton therapy and the European Particle Therapy Network: the past, present and future. Cancer Radiother. 2020;24(6-7):687–690.
   PubMed Web of Science ®Google Scholar
• Barcellini A, Mas FD, Paoloni P, et al. Please mind the gap—about equity and access to care in oncology. ESMO Open. 2021;6(6):100335. Internet [cited 2022 May 23]. Available from: https://www.esmoopen.com/article/S2059-7029(21)00297-0/fulltext.
   PubMed Web of Science ®Google Scholar
• Jaworski C, Mariani JA, Wheeler G, et al. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61(23):2319–2328.
   PubMed Web of Science ®Google Scholar
• Loap P, Servois V, Dhonneur G, et al. A radiotherapy contouring atlas for cardiac conduction node delineation. Pract Radiat Oncol. 2021;11:e434–e437.
   PubMed Web of Science ®Google Scholar
• Loap P, Marzi LD, Kirov K, et al. Development of simplified auto-segmentable functional cardiac atlas. Practic Radiat Oncol. 2022;S1879-8500(22)00055-8. DOI:10.1016/j.prro.2022.02.004
   Google Scholar
• Schneider U, Ernst M, Hartmann M. The dose-response relationship for cardiovascular disease is not necessarily linear. Radiat Oncol. 2017;12(1):74.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Wong AJ, Gunn GB, et al. Toward a model-based patient selection strategy for proton therapy: external validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiother Oncol. 2016;121(3):381–386.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol. 2020;10:e147–e154.
   PubMed Web of Science ®Google Scholar
• Loap P, Kirova Y. Evaluating cardiac substructure radiation exposure in breast rotational intensity modulated radiation therapy: effects of cancer laterality, fractionation and deep inspiration breath-hold. Cancer Radiother. 2021;25(1):13–20.
   PubMed Web of Science ®Google Scholar
• Chen VE, Song AJ, Werner-Wasik M, et al. Effect of radiation dose to cardiac substructures on the acute development of new arrhythmias following conventionally fractionated radiation treatment to the lung. Int J Radiat Oncol Biol Phys. 2019;105(1):E500.
   Web of Science ®Google Scholar
• Atkins KM, Chaunzwa TL, Lamba N, et al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. JAMA Oncol. 2021;7(2):206–219.
   PubMed Web of Science ®Google Scholar
• Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132(16):1635–1646.
   PubMed Web of Science ®Google Scholar
• Loap P, Tkatchenko N, Kirova Y. Evaluation of a delineation software for cardiac atlas-based autosegmentation: an example of the use of artificial intelligence in modern radiotherapy. Cancer Radiother. 2020;24(8):826–833.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
   PubMed Web of Science ®Google Scholar
• Kumar A, Casulo C, Advani RH, et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol. 2021;39(20):2257–2265.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223–234.
   PubMed Web of Science ®Google Scholar